golodirsen
Selected indexed studies
- Golodirsen. (, 2012) [PMID:32223119]
- Golodirsen: First Approval. (Drugs, 2020) [PMID:32026421]
- Golodirsen restores DMD transcript imbalance in Duchenne Muscular Dystrophy patient muscle cells. (Skelet Muscle, 2024) [PMID:39614336]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Adverse Drug Reactions and Toxicity of the Food and Drug Administration-Approved Antisense Oligonucleotide Drugs. (2022) pubmed
- Golodirsen. (2012) pubmed
- Golodirsen: First Approval. (2020) pubmed
- Golodirsen restores DMD transcript imbalance in Duchenne Muscular Dystrophy patient muscle cells. (2024) pubmed
- Golodirsen for Duchenne muscular dystrophy. (2020) pubmed
- Golodirsen (Vyondys 53) for Duchenne muscular dystrophy. (2020) pubmed
- The potential role and mechanism of circRNA/miRNA axis in cholesterol synthesis. (2023) pubmed
- Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs. (2022) pubmed
- RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges. (2020) pubmed
- Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. (2020) pubmed